PolyPid to Participate in Citizens JMP Life Sciences Conference
PolyPid to Participate in Citizens JMP Life Sciences Conference
PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that company management will present at the Citizens JMP Life Sciences Conference taking place in New York, NY, from May 13 – 14, 2024.
以色列PETACH TIKVA，2024年5月1日（環球新聞專線）——旨在改善手術效果的後期生物製藥公司Polypid Ltd.（納斯達克股票代碼：PYPD）（“Polypid” 或 “公司”）今天宣佈，公司管理層將出席2024年5月13日至14日在紐約州紐約舉行的Citizens JMP生命科學會議。
| Citizens JMP Life Sciences Conference Presentation | |
| Date: | Monday, May 13, 2024 |
| Time: | 2:30 PM ET |
| Citizens JMP 生命科學會議演講 | |
| 日期： | 2024 年 5 月 13 日，星期一 |
| 時間： | 美國東部時間下午 2:30 |
The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid around the conference should contact their Citizens JMP representative.
在本次活動期間，Polypid管理團隊將參加一對一的投資者會議。有興趣在會議期間與Polypid會面的投資者應聯繫其Citizens JMP代表。
About PolyPid
關於 PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
Polypid Ltd.（納斯達克股票代碼：PYPD）是一家處於後期階段的生物製藥公司，旨在改善手術結果。通過局部給藥、可控的延長釋放療法，Polypid的專有PLEX（聚合物脂質封裝矩陣）技術與活性藥物成分（API）相結合，能夠在數天至數月的持續時間內以最佳釋放速率精確交付藥物。Polypid 的主要候選產品 D-PLEX100 正在進行預防腹部結直腸手術部位感染的三期臨床試驗。此外，該公司目前正處於臨床前階段，以測試OncoPlex治療實體瘤的療效，首先是膠質母細胞瘤。
For additional Company information, please visit and follow us on Twitter and LinkedIn.
如需了解更多公司信息，請在 Twitter 和 LinkedIn 上訪問並關注我們。
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
聯繫人：
Polypid 有限公司
奧裏·沃沙夫斯基
COO——我們
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com
投資者：
布萊恩·裏奇
生命科學顧問
212-915-2578
britchie@lifesciadvisors.com
譯文內容由第三人軟體翻譯。